Product NDC: | 49702-217 |
Proprietary Name: | TRIZIVIR |
Non Proprietary Name: | abacavir sulfate, lamivudine, and zidovudine |
Active Ingredient(s): | 300; 150; 300 mg/1; mg/1; mg/1 & nbsp; abacavir sulfate, lamivudine, and zidovudine |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, FILM COATED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 49702-217 |
Labeler Name: | ViiV Healthcare Company |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021205 |
Marketing Category: | NDA |
Start Marketing Date: | 20101102 |
Package NDC: | 49702-217-18 |
Package Description: | 60 TABLET, FILM COATED in 1 BOTTLE (49702-217-18) |
NDC Code | 49702-217-18 |
Proprietary Name | TRIZIVIR |
Package Description | 60 TABLET, FILM COATED in 1 BOTTLE (49702-217-18) |
Product NDC | 49702-217 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | abacavir sulfate, lamivudine, and zidovudine |
Dosage Form Name | TABLET, FILM COATED |
Route Name | ORAL |
Start Marketing Date | 20101102 |
Marketing Category Name | NDA |
Labeler Name | ViiV Healthcare Company |
Substance Name | ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE |
Strength Number | 300; 150; 300 |
Strength Unit | mg/1; mg/1; mg/1 |
Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |